Anna Brown

Icon and Medpace report high R&D project cancellations; Icon sees $659M in Q1 cancellations, cuts guidance; Medpace notes early-stage trial reductions amid funding cuts

Roche plans $50B investment in US over 5 years for R&D and manufacturing, including 4 new facilities and expansions, amid Trump's potential pharma tariffs.

Fujifilm Diosynth Biotechnologies' bet on its North Carolina biologics facility is paying off, as Regeneron plans to shell out several billion dollars to move manufacturing to the site.

Trump's pharma tariffs prompt companies to assess vulnerabilities. J&J expects $400M in costs. Immunocore's Kimmtrak, Acadia's Nuplazid & Daybue may face impact. Companies highlight US manufacturing presence.

Commerce Secretary Howard Lutnick has indicated more specific timelines as to when pharma tariffs could surface, noting they are “coming in the next month or two.”

Pharma tool and packaging production companies are readying themselves for direct impact from President Donald Trump’s tariffs, which could then have a knock-on effect on their biopharma and CDMO customers.

President Donald Trump on Wednesday announced broad 10% global tariffs in a move that pharma industry groups worry will upend drug costs and manufacturing.

Multiple manufacturing updates: SHL Medical opens $220M SC factory, DHL acquires Cryopdp, AGC forms new division, new facilities for NBE, Siemens-Miko Ghana project, Cellares FDA designation & more industry developments.

J&J plans $55B US investment over 4 years, including 4 new factories. Construction begins on $2B NC biologics site, creating 500 jobs, following Lilly's $27B US manufacturing pledge.

A year after the Biosecure Act was introduced, WuXi AppTec’s US revenue growth continued to drop significantly, and the Chinese manufacturer failed to grow its customer base for the first time in five years. But the CDMO remains positive for an uptick this year.

Sutro Biopharma is reducing its headcount by 50%, appointing a new CEO, shutting down its only factory, and shifting away from its lead candidate.

Viking Therapeutics has contracted CDMO CordenPharma for a total of $150 million to make billions of clinical and commercial doses of its GLP-1/GIP receptor agonist for weight loss.

Eli Lilly opens unprecedented public submission process for US states to pitch potential manufacturing sites as part of $27B investment, with deadline set for March 12.

Bavarian Nordic CEO Paul Chaplin warns US pharma reshoring could take 5-10 years, citing tech transfer complexities. Company reassures it continues BARDA partnership and reveals new vaccine projects.

Pfizer CEO Bourla says company can shift operations from foreign sites to US manufacturing network to counter Trump's tariffs, citing 13 US factories as buffer.

Merck, Granules India, Bavarian Nordic lead manufacturing updates. News includes facility builds, acquisitions, partnerships, and EU's Caribbean investment in pharma manufacturing.

Ginkgo Bioworks’ stock $DNA fell by around 13% premarket Wednesday after the company dampened its 2025 sales forecast.

Amgen to invest $200M in new Hyderabad tech center through 2025, focusing on AI for drug development. Site opened Monday with plans to hire 3,000 employees.

Eli Lilly has amassed a stockpile of soon-to-be-launched drugs and related materials, primarily its oral GLP-1 candidate orforglipron, worth more than half a billion dollars.

Pfizer CEO Albert Bourla said its manufacturing business could be vulnerable from President Donald Trump’s tariffs in Europe as the big pharma has